Overview

Stem Cell Transplant for Bone Marrow Failure Syndromes

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord blood transplants in a safer manner by using less intensive therapy yet still achieve an acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure disorders.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Antilymphocyte Serum
Busulfan
Fludarabine
Fludarabine phosphate
Vidarabine